CEO Today Europe Awards

45 www.ceotodaymagazine.com CEO Today Europe Awards 2018 italy Q Q Our next goals are to develop different clinical applications and to allow product commercialization by the end of 2020. Two EU multicenter clinical studies in patients with non- loaded bone and load-bearing long bone defect (over 3 cm) are ready to begin. Product portfolio targeting spine fusion and drug–loaded scaffolds applications (bone cancer and bone infection) will be also developed. CE- mark and US FDA approval are expected by the end of 2019. The Global Orthopaedic Biomaterials market was US$6,700 million in 2013 and is expected to reach nearly US$11.2 billion by 2018 (CAGR 10,78%). GreenBone aims at >500M US$ in EU+USA peak sales. Market prospective and development achievements gave GreenBone the opportunity to close two oversubscribed rounds of financing, totaling 11.4€ million. I am grateful for our shareholders and investors who have trusted our team and our ambitious project and support our vision. We want to achieve great success with GreenBone and live up to our investors’ expectations. What technological advancements do you hope for that will help in the process of identifying and targeting future treatments? There are numerous fields where innovative technologies are making great progress. Considering new therapeutic approach, certainly cancer and degenerative diseases, such as Parkinson and Alzheimer, still represent major achievements all of us hope to see in the nearest future. MedTech and digital health are also extremely promising and in most cases, already a reality. I think that bio-sensoring and theragnostics will benefit disease management and reduce healthcare costs. I am excited to find out about possible connections between GreenBone and these technologies. Could you add a few words regarding your award and what it means for you to be recognized? I amhonored to receive this CEO Today award. GreenBone started off as a dream and over the past few years, it has been extremely fulfilling to see the company grow to its current state. I’d like to say a massive ‘thank you’ to our team and investors. And thank you for the award, CEO Today! GreenBone Ortho is transforming the treatment landscape for large bone defects. The company is developing a patented new generation biomimetic and resorbable bone graft for bone reconstruction. It is suitable for today’s unsolved non- loaded and load-bearing extensive bone damage: non-union fractures, trauma - cancer and infection induced bone loss, spinal fusion and others. The innovative idea is starting from wood to repair bone defects and provide patients the opportunity to return faster to normal life with their own bone completely regenerated: nature as a source of inspiration for better performing biocompatible and regenerative solutions. The idea was conceived and developed by a research group at ISTEC-CNR in Faenza (Institute of Science and Technology for Ceramics – National Research Council) led by Dr. Anna Tampieri. GreenBone Ortho srl was founded in 2014 in Faenza (Italy). GreenBone wood (Rattan)-derived bone regenerative implant is engineered to reflect anatomical and physiological bone composition and hierarchical structures: highly porous biomimetic calcium phosphate phases, endowed with bone-like morphology and very high mechanical strength. GreenBone is an EU class III Medical Device, FDA 510(k) USA. Since the beginning of 2015, the company has raised 11.4 € million from investments. Two EU clinical studies in patients with non-loaded bone and load-bearing long bone defect (over 3 cm) will allow for product market introduction in 2020. FIRM PROFILE Lorenzo Pradella has a Master’s Degree in Biological Science and a significant background in Pharmacology and Business in Innovation, with more than 25 years’ experience in R&D, Business Development and Venture Capital. He has held various senior positions in multinational companies such as Zambon Group SpA, Cardinal Health Inc. and Zcube srl (Research Venture of Zambon Group). As of 2008, Lorenzo has been working on vari- ous collaborations and investments with major university hubs in Europe, the United States and Israel, as well as with Mission Bay Capital and the California Institute for Quantitative Biosciences (QB3), headquartered in the UCSF Mission Bay campus. Lorenzo was also a Board member of several BioTech start-ups and the President of Italy’s HealthCare Licensing Group (ItalyHLG) be- tween 2010 and 2014. ABOUT LORENZO PRADELLA www.greenbone.it